Supplementary Figure 2. The proportions of patients with serum HBV DNA levels <3 log IU/mL, 3–4 log IU/mL, and >4 log IU/mL by the absence or presence of clinical relapses were respectively 100% vs. 100%, 0 vs. 0, and 0 vs. 0 at treatment cessation (A), 68.4% (n=54) vs. 45.7% (n=16), 17.7% (n=14) vs. 20.0% (n=7), and 13.9% (n=11) vs. 34.3% (n=12) at the first year (B), and 63.2% (n=36) vs. 42.9% (n=6), 24.5% (n=14) vs. 42.9% (n=6), and 12.3% (n=7) vs. 14.2% (n=2), respectively, at the second year (C). HBV, hepatitis B virus; CR, clinical relapse.